News

Unibest NewCo & Licensing Pipeline

Views: 1778     Author: Unibest Industrial     Publish Time: 2025-08-29      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button

Last Updated: 2025-08-29

ADC

CodeTargetIndicationPreclinicalPh IPh IIPh IIINDA/BLADetail
UB323FGFR2b, DNA Topoisomerase IAdvanced solid tumor

UB319ROR1, DNA Topoisomerase IAdvanced solid tumor as monotherapy

UB318ROR1, DNA Topoisomerase IMCL, DLBCL, cHL as monotherapy

UB044Microtubule (ADC payload)HER2- breast cancer; HER2+ gastric cancer

UB322MUC17, DNA Topoisomerase IAdvanced solid tumor

UB320ROR1, DNA Topoisomerase IDLBCL as combination therapy

UB321CDH17, DNA Topoisomerase IGI cancer

UB032Nectin-4/Trop2Bladder cancer; cervical cancer; lung cancer

UB031cMet/HER2Pancreatic cancer; lung cancer; gastrointestinal cancer; renal cancer

UB022HER2/Trop2Breast cancer; cervical cancer; gastric cancer

UB127EGFR;cMetLung Cancer

UB126ADAM9Gastrointestinal Cancer

UB138Undisclosed (BsAb+Dual-payload)Solid tumors

UB137Undisclosed (mAb+Dual-payload)Solid tumors

UB136BsAb + Dual-payloadSolid tumors

UB134EGFR Bi-epitope + Dual-payloadCRC,HNSC,PAAD,NSCLC,etc.

UB189B7H3 BsAb + Dual-payloadSCLC

UB191TROP2 BsAb + Dual-payloadPancreatic cancer

UB190B7H3 Bi-functional+ Dual-payloadProstate cancer

UB188DLL3 BsAb + Dual-payloadSCLC; neuroendocrine neoplasm

Antibody

CodeTargetIndicationPreclinicalPh IPh IIPh IIINDA/BLADetail
UB187PD1Recurrent or metastatic thymic carcinoma that has failed first-line chemotherapy

UB302VEGF-AMoist age-related macular degeneration

UB186EGFRColorectal cancer

UB053PDL1; 4-1BBExtrapulmonary Neuroendocrine Carcinomas

UB331IL-4RαAtopic dermatitis

UB330IL-4RαPrutigo nodularis

UB013LAG3Solid tumors and lymphoma; autoimmune

UB014EGFR; CD3Metastatic breast cancer; gastric cancer

UB056PDL1; 4-1BBNSQ-NSCLC; NSCLC; biliary cancer; solid tumor (+ radiotherapy; +/- VEGF)

UB055PDL1; 4-1BBExtrapulmonary Neuroendocrine Carcinomas; NSCLC (+ radiotherapy)

UB054PDL1; 4-1BBNSCLC; biliary cancer; solid tumor

UB149AβAlzheimer's Disease

UB060MUC16; CD3Ovarian cancer; cervical cancer; solid tumor

UB015EGFR; CD3 (enzyme-controlled)Solid tumors

UB017IL-12 prodrugSolid tumors

UB019GPC3; CD3Hepatocellular carcinoma

UB058GPRC5D; CD3MM

UB266CD38Multiple myeloma

UB333(BsAb)IgA nephropathy

UB332(BsAb)IBD, PsO, PsA

UB061MUC16; CD3Solid tumor (US)

UB059GPRC5D; CD3MM (US)

UB041HERV-K Env-TMAll cancer

UB023PD-L1; VEGFLung cancer; breast cancer

UB018RORI; CD3Lymphoma; breast cancer

UB267CD38Multiple myeloma

UB020PD-1/IL-15 cytokine antibody conjudgateSolid tumors

UB057PDL1; 4-1BBSolid tumor (US)

CGT

CodeTargetIndicationPreclinicalPh IPh IIPh IIINDA/BLADetail
UB038TGFβ1; COX-2 (siRNA)NMSC

UB084(Oncolytic virus)Metastatic refractory tumors, including squamous cell carcinoma of the head and neck, lung cancer, ovarian cancer, sarcoma, triple-negative breast cancer, and other sensitive tumors.
About
UB098HBVHepatocelluar Carcinoma

UB139PCSK9 (siRNA)Hypercholesteremia

UB099HBVCholangio-carcinoma

UB039TGFβ1; COX-2 (siRNA)Focal Fat Reduction

UB145Factor XI (siRNA)Anticoagulation, Stroke

UB144(siRNA)Solid tumors

UB101HPVCervical, Head & Neck Cancer

UB100HBVChronic Hepatitis B

UB085(Oncolytic virus)Metastatic refractory tumors, including squamous cell carcinoma of the head and neck, lung cancer, ovarian cancer, sarcoma, triple-negative breast cancer, and other sensitive tumors. （US）
About
UB140PCSK9 (siRNA)Hypercholesteremia

UB092(siRNA)Age-related macular degeneration

UB090Calcineurin/Fn14 (siRNA)Organ transplant; autoimmune

UB089IL4R (siRNA)Atopic dermatitis

UB146ApoC3 (siRNA)Hypertriglyceridemia

UB097(siRNA)Melanoma

UB096SGLT2 (siRNA)Type 2 Diabetes; ghout

UB095(siRNA)Nephrotic syndrome

UB103(iPSC)Solid tumor

UB102EBVSolid tumor

UB094FcRn (siRNA)Myasthenia gravis

UB091Glucosylceramide synthase (siRNA)Gaucher/Fabry

UB093Renin / AGTHypertension

Fusion Protein

CodeTargetIndicationPreclinicalPh IPh IIPh IIINDA/BLADetail
UB326FGF21R, GCGR, GLP-1 RSevere hypertriglyceridemia

UB325FGF21R, GCGR, GLP-1 RMAFLD

UB329CLDN18.2Advanced solid tumor

UB328PDL1, VEGF, TGF-βGI cancer

UB327PDL1, VEGF, TGF-βNSCLC

Peptide

CodeTargetIndicationPreclinicalPh IPh IIPh IIINDA/BLADetail
UB011GLP-1 RDiabetes

UB080GLP-1Obesity

UB298Insulin receptorType 2 diabetes

UB012GLP-1 RObesity

UB081GLP-1MASH

UB315GLP-1; GIPWeight management

UB316GLP-1; GIPDiabetes

UB045GLP-1Type 2 Diabetes (US)

UB047GLP-1;GCGObesity

UB285Tumor neuantigensPancreatic cancer (personalized cancer vaccaine)

UB049μ opioid receptorOIC

UB048GLP-1;GCGMASH (US)

UB263GLP-1 RCVOT in T2DM

UB317GLP-1; GIPMAFLD/MASH, OSA, HFpEF

UB046GLP-1Type 2 Diabetes + SGLT-2

UB050GCGRCongenital hyperinsulinism

UB051GLP-1; GIPType 2 Diabetes; Obesity; MASH

UB052GLP-1R; GIPR; GCGRType 2 Diabetes; Obesity; MASH

UB104GLP-1 (Oromucosal)Diabetes; Obesity
About
UB010GLP-1 RDiabetes

Small Molecule

CodeTargetIndicationPreclinicalPh IPh IIPh IIINDA/BLADetail
UB228CHRM3COPD
ANDA

UB226β2 AR, Glucocorticoid receptorAsthma and COPD
ANDA

UB202Lanosterol 14-alpha demethylaseInvasive aspergillosis and mucormycosis
ANDA

UB247SDAMAtypical antipsychotic indicated for: • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older. • Treatment of agitation associated with dementia due to Alzheimer’s disease.

UB311Free radical scavengerCerebral ischemic stroke

UB314EGFR (L858R)NSCLC

UB082F protein (RSV)RSV

UB309JAK1, JAK2Vitiligo

UB312GLP-1 (oral)Weight management

UB063HBV CaspidCHB

UB065P2Y12RACS

UB066P2Y12RACS; Ischemic stroke; peripheral arterial disease

UB067JAK1 (topical)Moderate to severe atopic dermatitis

UB068JAK1 (oral)Ankylosing spondylitis

UB313GLP-1 (oral)Diabetes

UB062KCNQ2/3Epilepsy (AU)

UB0425-HT; DAASD

UB24917-α-hydroxylaseMetastatic castration-resistant prostate cancer patients who have received prior chemotherapy containing docetaxel

UB310JAK1, JAK2Prutigo nodularis

UB024KV1.3 (Topical)Atopic dermatitis
About
UB083F protein (RSV)RSV prevention

UB147Keratin, PlasminMelasma

UB176KV1.3 (Topical)Psoriasis
About
UB064TEADOncology

UB026PI3K-Akt-mTOR pathwayMelanoma; esophageal cancer, colorectal cancer

UB027mTORC2Neuroendocrine tumors; lung cancer; breast cancer

UB028FXIaThrombus

UB069RIPK1Peripheral arterial diseases; primary biliary cirrhosis

UB177KV1.3 (Oral)Atopic dermatitis
About
UB148Androgen receptorAcne

UB284AChEMyasthemia gravis

UB029KV1.3 (Oral)Inflammatory bowel disease
About
UB030cMyc pathwayGynecological tumors

UB248NMDAModerate to severe dementia of the Alzheimer’s type

UB070pan-RAS (on)Solid tumor

UB043Agmatinase, Imidazoline Rc, NMDA RcASD

UB040Multiple targets; immunostimulantsAll cancer

UB178KV1.3 (Topical)Alopecia
About
UB179GPCRDiabetic retinopathy; age related macular degeneration

UB180GPCROcular inflammatory diseases

UB181GPCRCOPD

UB182Ion channel inhibitorPruritus

UB183Ion channel inhibitorDiabetic nephropathy

UB125GABAA ReceptorEpilepsy

UB229Glucocorticoid receptor, CHRM3, β2 ARCOPD

Targeted Protein Degradation

CodeTargetIndicationPreclinicalPh IPh IIPh IIINDA/BLADetail
UB025cMycPancreatic cancer
About
UB324HPK-1Advanced solid tumor

NewCo license out antibody small molecule ADC recombinant protein CGT targeted protein degradation